The Thirty Years War that reshaped Europe featured myriad twists and turns. The Krill Wars have, too, with the latest being a final, formal burying of the hatchet between the two principal players, Aker BioMarine and Neptune Technologies and Bioressources.
The long-running krill oil patent dispute between Canada’s Neptune Technologies & Bioressources and Israel-based Enzymotec Ltd. has come to an end, with the firms signing a final and binding patent infringement settlement and license agreement.
French probiotic leader Danone, Swedish dairy firm Skånemejerier and ingredient supplier Probi yesterday closed a three-way probiotic juice deal, bringing the firms one step closer to an international launch of the ProViva brand.
Naturex has unveiled new websites for the branded health
ingredients in its Nat'Life division, to give end consumers in
Italy, Spain and Germany information on the brands in their own
languages.
Swiss biotech giant Syngenta is to form a joint venture and
licensing agreement in the US with DuPont, a move designed to
expand access to the firms corn and soybean genetics and
biotechnology traits.
UK-based ReGen Therapeutics has been granted a US patent on its
peptide nutraceutical Colostrinin, which it is planning to
introduce in the North American market as a dietary supplement for
cognitive health.
Novogen is blaming lower US sales of its red clover-based
supplements in the first six months of 2004 on consumer confusion
due to the conflicting publicity regarding the safety and efficacy
of HRT and natural menopause products.
UK firm Phytopharm, which has isolated the appetite-suppressing
ingredients in the desert plant hoodia, says it is in advanced
talks to license its compound to a food industry partner.
Australian biotech firm Novogen has been granted a US patent
covering the use of soy isoflavones in tablet or capsule dietary
supplements, it revealed last week.
Humanetics of the US has signed a licensing agreement with
compatriot iSatori which will see its anti-ageing supplement 7-Keto
adapted for use as a weight loss product.
A licence granting Carolwood Corporation the right to produce
products containing methyl-sulfonyl-methane (MSM) has been revoked
by the product's creator MSM Investments.
Forbes Medi-Tech has said it will not exercise its right to buy
back the licensing and distribution rights to Reducol, the
cholesterol-lowering ingredient from Novartis.
